EOLS
Price
$5.99
Change
+$0.01 (+0.17%)
Updated
Sep 26 closing price
Capitalization
387.47M
44 days until earnings call
NBIX
Price
$142.00
Change
+$1.11 (+0.79%)
Updated
Sep 26 closing price
Capitalization
14.08B
37 days until earnings call
Interact to see
Advertisement

EOLS vs NBIX

Header iconEOLS vs NBIX Comparison
Open Charts EOLS vs NBIXBanner chart's image
Evolus
Price$5.99
Change+$0.01 (+0.17%)
Volume$1.28M
Capitalization387.47M
Neurocrine Biosciences
Price$142.00
Change+$1.11 (+0.79%)
Volume$980.29K
Capitalization14.08B
EOLS vs NBIX Comparison Chart in %
Loading...
EOLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NBIX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EOLS vs. NBIX commentary
Sep 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EOLS is a Buy and NBIX is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 28, 2025
Stock price -- (EOLS: $5.99 vs. NBIX: $142.00)
Brand notoriety: EOLS and NBIX are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: EOLS: 83% vs. NBIX: 108%
Market capitalization -- EOLS: $387.47M vs. NBIX: $14.08B
EOLS [@Pharmaceuticals: Generic] is valued at $387.47M. NBIX’s [@Pharmaceuticals: Generic] market capitalization is $14.08B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.82B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EOLS’s FA Score shows that 0 FA rating(s) are green whileNBIX’s FA Score has 1 green FA rating(s).

  • EOLS’s FA Score: 0 green, 5 red.
  • NBIX’s FA Score: 1 green, 4 red.
According to our system of comparison, NBIX is a better buy in the long-term than EOLS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EOLS’s TA Score shows that 4 TA indicator(s) are bullish while NBIX’s TA Score has 4 bullish TA indicator(s).

  • EOLS’s TA Score: 4 bullish, 4 bearish.
  • NBIX’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, EOLS is a better buy in the short-term than NBIX.

Price Growth

EOLS (@Pharmaceuticals: Generic) experienced а -4.77% price change this week, while NBIX (@Pharmaceuticals: Generic) price change was -2.22% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -1.16%. For the same industry, the average monthly price growth was +24.25%, and the average quarterly price growth was +66.99%.

Reported Earning Dates

EOLS is expected to report earnings on Nov 11, 2025.

NBIX is expected to report earnings on Nov 04, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (-1.16% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NBIX($14.1B) has a higher market cap than EOLS($387M). NBIX YTD gains are higher at: 4.029 vs. EOLS (-45.743). NBIX has higher annual earnings (EBITDA): 557M vs. EOLS (-33.58M). NBIX has more cash in the bank: 976M vs. EOLS (61.7M). EOLS has less debt than NBIX: EOLS (155M) vs NBIX (439M). NBIX has higher revenues than EOLS: NBIX (2.51B) vs EOLS (278M).
EOLSNBIXEOLS / NBIX
Capitalization387M14.1B3%
EBITDA-33.58M557M-6%
Gain YTD-45.7434.029-1,135%
P/E RatioN/A42.01-
Revenue278M2.51B11%
Total Cash61.7M976M6%
Total Debt155M439M35%
FUNDAMENTALS RATINGS
EOLS vs NBIX: Fundamental Ratings
EOLS
NBIX
OUTLOOK RATING
1..100
5188
VALUATION
overvalued / fair valued / undervalued
1..100
92
Overvalued
75
Overvalued
PROFIT vs RISK RATING
1..100
8370
SMR RATING
1..100
10058
PRICE GROWTH RATING
1..100
9546
P/E GROWTH RATING
1..100
10027
SEASONALITY SCORE
1..100
n/a17

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NBIX's Valuation (75) in the Biotechnology industry is in the same range as EOLS (92) in the Pharmaceuticals Major industry. This means that NBIX’s stock grew similarly to EOLS’s over the last 12 months.

NBIX's Profit vs Risk Rating (70) in the Biotechnology industry is in the same range as EOLS (83) in the Pharmaceuticals Major industry. This means that NBIX’s stock grew similarly to EOLS’s over the last 12 months.

NBIX's SMR Rating (58) in the Biotechnology industry is somewhat better than the same rating for EOLS (100) in the Pharmaceuticals Major industry. This means that NBIX’s stock grew somewhat faster than EOLS’s over the last 12 months.

NBIX's Price Growth Rating (46) in the Biotechnology industry is somewhat better than the same rating for EOLS (95) in the Pharmaceuticals Major industry. This means that NBIX’s stock grew somewhat faster than EOLS’s over the last 12 months.

NBIX's P/E Growth Rating (27) in the Biotechnology industry is significantly better than the same rating for EOLS (100) in the Pharmaceuticals Major industry. This means that NBIX’s stock grew significantly faster than EOLS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EOLSNBIX
RSI
ODDS (%)
Bullish Trend 3 days ago
90%
Bearish Trend 3 days ago
70%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
76%
Bearish Trend 3 days ago
54%
Momentum
ODDS (%)
Bearish Trend 3 days ago
76%
Bullish Trend 3 days ago
77%
MACD
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
67%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
83%
Bearish Trend 3 days ago
58%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
82%
Bullish Trend 3 days ago
72%
Advances
ODDS (%)
Bullish Trend 24 days ago
79%
Bullish Trend 11 days ago
72%
Declines
ODDS (%)
Bearish Trend 4 days ago
81%
Bearish Trend 14 days ago
58%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
75%
Bearish Trend 3 days ago
79%
Aroon
ODDS (%)
Bearish Trend 3 days ago
75%
Bullish Trend 3 days ago
75%
View a ticker or compare two or three
Interact to see
Advertisement
EOLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NBIX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TIMCF1.060.09
+9.46%
Titan Mining Corporation
CMWAY108.350.99
+0.92%
Commonwealth Bank of Australia
PHMMF99.90N/A
N/A
Pharma Mar SA
WRFRF2.82-0.06
-2.09%
Wharf Real Estate Investment Co Ltd.
LMSQF0.14N/A
-3.41%
Latin Metals Inc.

EOLS and

Correlation & Price change

A.I.dvisor indicates that over the last year, EOLS has been loosely correlated with PRGO. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if EOLS jumps, then PRGO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EOLS
1D Price
Change %
EOLS100%
+0.17%
PRGO - EOLS
44%
Loosely correlated
+3.32%
AMRX - EOLS
33%
Poorly correlated
+1.56%
LNTH - EOLS
32%
Poorly correlated
-1.67%
ALKS - EOLS
30%
Poorly correlated
+2.80%
NBIX - EOLS
29%
Poorly correlated
+0.79%
More

NBIX and

Correlation & Price change

A.I.dvisor indicates that over the last year, NBIX has been loosely correlated with ELAN. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if NBIX jumps, then ELAN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NBIX
1D Price
Change %
NBIX100%
+0.79%
ELAN - NBIX
33%
Loosely correlated
+3.65%
LFCR - NBIX
32%
Poorly correlated
+2.94%
CGC - NBIX
31%
Poorly correlated
-2.19%
ALKS - NBIX
31%
Poorly correlated
+2.80%
AQST - NBIX
30%
Poorly correlated
+13.88%
More